Description | FUNCTION:Cysteineproteaserequiredforautophagy,whichcleavestheC-terminalpartofeitherMAP1LC3,GABARAPL2orGABARAP,allowingtheliberationofformI.AsubpopulationofformIissubsequentlyconvertedtoasmallerform(formII).FormII,witharevealedC-terminalglycine,isconsideredtobethephosphatidylethanolamine(PE)-conjugatedform,andhasthecapacityforthebindingtoautophagosomes.ENZYMEREGULATION:InhibitedbyN-ethylmaleimide.SUBCELLULARLOCATION:Cytoplasm(Probable).ALTERNATIVEPRODUCTS:5namedisoformsproducedbyalternativesplicing.TISSUESPECIFICITY:Mainlyexpressedintheskeletalmuscle,followedbybrain,heart,liverandpancreas.SIMILARITY:BelongstothepeptidaseC54family. |
BatchNo. | Seeproductlabel |
Unitsize | 100µl |
Antigen | Asyntheticpeptide(CLERFFDSEDED)correspondingtotheC-terminusofhumanATG4BproteinconjugatedtoBlueCarrierProteinhasbeenusedastheimmunogen.ThepeptideishomologouswiththecorrespondingsequencederivedfromofATG4Bproteininmouseandrat. |
OtherNames | CysteineproteaseATG4B;Autophagy-relatedprotein4homologB;hAPG4B;Autophagin-1;Autophagy-relatedcysteineendopeptidase1;AUT-like1cysteineendopeptidase;ATG4B;APG4B;AUTL1;KIAA0943; |
Accession | ATG4B_HUMAN ATG4B_MOUSE ATG4B_RAT |
Producedin | Rabbit |
Purity | Wholeserum |
Applications | IHC,immunofluorescence,WB.Adilutionof1:100to1:2000dilutionisrecommendedfortheseapplications.Biosensisrecommendsoptimaldilutions/concentrationsshouldbedeterminedbytheenduser. |
Specificity | IHC,WBandELISAconfirmedthespecificityforATG4B. |
Cross-reactivity | Human,rat.Otherspeciesnotyettested. |
Form | Lyophilised |
Reconstitution | Reconstitutein100µlofsterilewater.Centrifugetoremoveanyinsolublematerial. |
Storage | Afterreconstitutionkeepaliquotsat-20ºCforahigherstABIlity,andat4ºCwithanappropriateantibacterialagent.Glycerol(1:1)maybeaddedforanadditionalstability.Avoidrepetitivefreeze/thawcycles. |
ExpiryDate | Sixmonthsafterpurchase |
SpecificReferences | 1.A.J.Smuderetal(2011)Exerciseprotectsagainstdoxorubicin-inducedMarkersofautophagysignalinginskeletalmuscle.JApplPhysiol.2011Jul21 |
References | 1.MarinoG,etal.J.Biol.Chem.278:3671-3678(2003). 2.KabeyaY,etal.J.CellSci.117:2805-2812(2004). 3.NagaseT,etal.DNARes.6:63-70(1999). 4.OtaT,etal.Nat.Genet.36:40-45(2004). 5.SugawaraK,etal.J.Biol.Chem.280:40058-40065(2005). 6.KumanomidouT,etal.J.Mol.Biol.355:612-618(2006). |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。